Biogen Backs Alzheimer's Tau Drug for Phase 3 Despite Trial Miss

Biogen (BIIB) reported Phase 2 CELIA data for diranersen in early Alzheimer’s, stating the results provide proof of concept for its tau-targeting approach. However, the study did not meet its primary endpoint requiring a predefined dose-response pattern. Net takeaway is a cautious signal: scientific rationale remains intact, but clinical efficacy endpoints fell short.

Analysis

Biogen (BIIB) reported Phase 2 CELIA data for diranersen in early Alzheimer’s, stating the results provide proof of concept for its tau-targeting approach. However, the study did not meet its primary endpoint requiring a predefined dose-response pattern. Net takeaway is a cautious signal: scientific rationale remains intact, but clinical efficacy endpoints fell short.